methotrexate pfizer (methotrexate wyeth) tafla 2,5 mg
pfizer aps - methotrexatum inn - tafla - 2,5 mg
cytarabine pfizer stungulyf/innrennslislyf, lausn 100 mg/ml
pfizer aps - cytarabinum inn - stungulyf/innrennslislyf, lausn - 100 mg/ml
s-ketamin pfizer stungulyf, lausn 25 mg/ml
pfizer aps - esketaminum hýdróklóríð - stungulyf, lausn - 25 mg/ml
tranexamsyre pfizer (cyklokapron stungulyf, lausn) stungulyf/innrennslislyf, lausn 100 mg/ml
pfizer aps - tranexamic acid - stungulyf/innrennslislyf, lausn - 100 mg/ml
pamidronatdinatrium pfizer innrennslisþykkni, lausn 9 mg/ml
pfizer aps - pamidronat dínatríum - innrennslisþykkni, lausn - 9 mg/ml
pamidronatdinatrium pfizer innrennslisþykkni, lausn 6 mg/ml
pfizer aps - pamidronat dínatríum - innrennslisþykkni, lausn - 6 mg/ml
pamidronatdinatrium pfizer innrennslisþykkni, lausn 3 mg/ml
pfizer aps - pamidronat dínatríum - innrennslisþykkni, lausn - 3 mg/ml
pemetrexed pfizer (previously pemetrexed hospira)
pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - Æxlishemjandi lyf - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
solu-medrol stungulyfsstofn og leysir, lausn 40 mg
pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 40 mg
pro-epanutin stungulyf, lausn/innrennslisþykkni, lausn 50 mg fe/ml
pfizer aps - fosphenytoinum dínatríum - stungulyf, lausn/innrennslisþykkni, lausn - 50 mg fe/ml